Nanobiotix SA announced that Dr. Alain Herrera joins its Supervisory Board, succeeding Thierry Chopin and Isabelle Bou Antoun in their roles, as part of a planned Supervisory Board succession. Dr. Herrera joins Nanobiotix Supervisory Board with more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing. Before setting up his own oncology consultancy, Alain Oncologie Consulting (AOC), he headed the Oncology business at Sanofi-Aventis for ten years, where he was Vice President for the Global Oncology Business Strategy and Development (2007-2008) and Head of the Global Oncology Franchise (1998-2007).

He contributed to the worldwide registration of Oxaliplatin (Eloxatin(R)) and Rasburicase (Fasturtec(R)/Elitek(R)), as well as the Gastric and Head & Neck indications for Docetaxel (Taxotere(R)). His previous responsibilities within the pharmaceutical industry included the roles of Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rh Net Poulenc). In addition to these roles, since 1991, Dr. Herrera has been a Hematologist Consultant at Antoine Beclere Hospital.